Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Primary endpoint During the median follow-up of 20 months(ranging from 6 to 48 months), the incidence of MACEs was significantly lower in the GLP-1RA group (7.63%) compared to the control group (19.85%) (HR 0.444
EXSCEL compared extended release exenatide to placebo in 14,752 patients with T2DM and established CV disease or CV risk factors only [18]
However, the two have not been directly compared in a head-to-head trial, and retatrutide is not yet approved for use
L-carnitine use in dialysis research subjects: is national coverage for [PMID: 12715624] Laboratory literature summary: L-carnitine use in dialysis research subjects: is national coverage for supplementation justified
Permuth et al., 2018)
US$ 21.18
US$ 25.31
US$ 21.22
US$ 21.93
